Clinical Trial Update: Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on NBI-98854 assessing safety and efficacy in adults with Tourette Syndrome; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2020-05-07